Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30381252 | 1.00 | KDM4E (0.41) | KDM4EGBA1HTTCKS1BSKP2 | |
| SCHEMBL20783101 | 0.88 | CYP17A1 (0.44) | KDM4EGBA1HTTCKS1BSKP2 | |
| SCHEMBL12065790 | 0.85 | CCNA2 (0.39) | KDM4EGBA1HTTCKS1BSKP2 | |
| SCHEMBL20839859 | 0.84 | ENPP3 (0.39) | KDM4EHTTALDH1A1CCNA2CDK2 | |
| SCHEMBL20765211 | 0.81 | HTR6 (0.47) | MAPTLMNACDK2HTR6PTGDR2 | |
| SCHEMBL30380898 | 0.81 | HTR6 (0.47) | MAPTLMNACDK2HTR6PTGDR2 | |
| SCHEMBL15586649 | 0.78 | ENPP3 (0.39) | KDM4EHTTMAPTALDH1A1CDK2 | |
| SCHEMBL16546218 | 0.77 | PTGDR2 (0.45) | KDM4EGBA1MAPTALDH1A1LMNA | |
| SCHEMBL30751163 | 0.75 | L3MBTL1 (0.43) | GBA1HTTMAPTLMNATP53 | |
| SCHEMBL30751160 | 0.75 | L3MBTL1 (0.43) | GBA1HTTMAPTLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322772-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-10-12 | — | — | US | disclosed |
| US-20230322772-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-10-12 | — | — | US | disclosed |
| US-20230322772-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-10-12 | — | — | US | disclosed |
| US-11498919-B2 | Azaindolylpyridone and diazaindolylpyridone compounds | SPRINT BIOSCIENCE AB (SE) | 2022-11-15 | — | — | US | disclosed |
| EP-4001278-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| EP-4001278-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| EP-3672967-B1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3672967-B1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210122745-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2021-04-29 | — | — | US | disclosed |
| US-20210122745-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2021-04-29 | — | — | US | disclosed |
| EP-3672967-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019038384-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322772-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | AZI2, IAPP, ZFX | KDM4E 181/4885GBA1 2515/4885HTT 1306/4885 |
| US-20210122745-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | AZI2, IAPP, ZFX | KDM4E 181/4885GBA1 2515/4885HTT 1306/4885 |
| US-11498919-B2 | Azaindolylpyridone and diazaindolylpyridone compounds | AZI2, IAPP, ZFX | KDM4E 181/4885GBA1 2515/4885HTT 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.